Sunesis appoints Joseph DePinto as Chief Commercial Officer Sunesis Pharmaceuticals (SNSS) announced the appointment of Joseph DePinto to the newly created position of executive vice president and Chief Commercial Officer. Prior to joining Sunesis, DePinto was Executive Vice President, Global Commercial Operations at Dendreon (DNDN).
Sunesis to submit MAA for vosaroxin with EMA by end of 2015 Sunesis Pharmaceuticals announced that the company intends to submit a Marketing Authorization Application for vosaroxin as a treatment for acute myeloid leukemia with the European Medicines Agency by the end of 2015. The company recently announced that it met separately with the Rapporteur (United Kingdom) and Co-Rapporteur (Netherlands) assigned to provide advice and guidance to the company through the MAA process. Based on these discussions, the company is proceeding with an MAA filing for the indication of relapsed/refractory AML in patients age 60 years and older, a population with the greatest medical need and for whom the greatest benefit was observed in the vosaroxin/cytarabine treatment arm of VALOR, the company's pivotal Phase 3 study of vosaroxin and cytarabine in adult patients with relapsed or refractory AML.